Ali Tehrani is the founder of Zymeworks. Zymeworks has raised $360M in total funding. Latest round: IPO. Based in Vancouver, Canada.
Ali Tehrani is the Co-Founder and CEO of Zymeworks, a phase 3 clinical-stage biotechnology company developing multi-functional protein therapeutics for HER2+ cancers. He previously raised nearly $30 million through angel investments before leading Zymeworks' nearly $60 million IPO in 2017 and subsequent $300 million+ follow-on rounds. Tehrani is now CEO and Co-Founder of DCx Biotherapeutics Corporation, a company spun out from Zymeworks.
Full founder directory · Investor directory · Company funding database · Fundraising library